RxDoctor Payments Data

Julie Archer, MD

Internal Medicine · Chico, CANPI 1962409573

Payments from drug & device makers

$3,086in general payments, 2019–2025

Across 146 payments — averaging $21.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Boehringer Ingelheim$318
  • Lilly USA, LLC$301
  • AstraZeneca$201
  • Pfizer$144
  • Astellas Pharma US Inc$127
  • plus $844 from 25 others

What the payments were for

  • Food & beverage$3,02598%
  • Education$612%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,086 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$385,461
Medicare patients
905
Services billed
4,846

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide110$107,912
JardianceEmpagliflozin93$86,652
EliquisApixaban69$55,954
TrulicityDulaglutide42$55,067
RybelsusSemaglutide34$50,975
Teriparatide23$30,175
XareltoRivaroxaban28$29,287
MyrbetriqMirabegron27$25,702
WegovySemaglutide17$25,424
MounjaroTirzepatide18$22,159
CreonLipase/Protease/Amylase15$21,799
JanuviaSitagliptin Phosphate19$19,485
Spiriva HandihalerTiotropium Bromide17$11,257
OxycontinOxycodone Hcl12$10,219
Levothyroxine Sodium682$8,880

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy, Tresiba$56$192,248173 claims
Boehringer IngelheimJardiance$318$86,65293 claims
Lilly USA, LLCTrulicity, Mounjaro$301$77,22660 claims
PfizerEliquis$144$55,95469 claims
AbbVieCreon, Synthroid$1,151$27,663118 claims
Astellas Pharma US IncMyrbetriq$127$25,70227 claims
MerckJanuvia$27$19,48519 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$27$6,58112 claims
AstraZenecaPulmicort Flexhaler$201$3,20614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Chico

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →